Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by lklinares
Group name EquipeLL
Item Type Journal Article
Title Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism
Creator Farge et al.
Author Thomas Farge
Author Estelle Saland
Author Fabienne de Toni
Author Nesrine Aroua
Author Mohsen Hosseini
Author Robin Perry
Author Claudie Bosc
Author Mayumi Sugita
Author Lucille Stuani
Author Marine Fraisse
Author Sarah Scotland
Author Clément Larrue
Author Héléna Boutzen
Author Virginie Féliu
Author Marie-Laure Nicolau-Travers
Author Stéphanie Cassant-Sourdy
Author Nicolas Broin
Author Marion David
Author Nizar Serhan
Author Audrey Sarry
Author Suzanne Tavitian
Author Tony Kaoma
Author Laurent Vallar
Author Jason Iacovoni
Author Laetitia K. Linares
Author Camille Montersino
Author Rémy Castellano
Author Emmanuel Griessinger
Author Yves Collette
Author Olivier Duchamp
Author Yara Barreira
Author Pierre Hirsch
Author Tony Palama
Author Lara Gales
Author François Delhommeau
Author Barbara H. Garmy-Susini
Author Jean-Charles Portais
Author François Vergez
Author Mary Selak
Author Gwenn Danet-Desnoyers
Author Martin Carroll
Author Christian Récher
Author Jean-Emmanuel Sarry
Abstract Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC). To validate this hypothesis in vivo, we developed a clinically relevant chemotherapeutic approach treating patient-derived xenografts (PDX) with cytarabine (AraC). AraC residual AML cells are enriched in neither immature, quiescent cells nor LSCs. Strikingly, AraC-resistant preexisting and persisting cells displayed high levels of reactive oxygen species, showed increased mitochondrial mass, and retained active polarized mitochondria, consistent with a high oxidative phosphorylation (OXPHOS) status. AraC residual cells exhibited increased fatty-acid oxidation, upregulated CD36 expression, and a high OXPHOS gene signature predictive for treatment response in PDX and patients with AML. High OXPHOS but not low OXPHOS human AML cell lines were chemoresistant in vivo. Targeting mitochondrial protein synthesis, electron transfer, or fatty-acid oxidation induced an energetic shift toward low OXPHOS and markedly enhanced antileukemic effects of AraC. Together, this study demonstrates that essential mitochondrial functions contribute to AraC resistance in AML and are a robust hallmark of AraC sensitivity and a promising therapeutic avenue to treat AML residual disease.Significance: AraC-resistant AML cells exhibit metabolic features and gene signatures consistent with a high OXPHOS status. In these cells, targeting mitochondrial metabolism through the CD36-FAO-OXPHOS axis induces an energetic shift toward low OXPHOS and strongly enhanced antileukemic effects of AraC, offering a promising avenue to design new therapeutic strategies and fight AraC resistance in AML. Cancer Discov; 7(7); 716-35. ©2017 AACR.See related commentary by Schimmer, p. 670This article is highlighted in the In This Issue feature, p. 653.
Publication Cancer Discovery
Volume 7
Issue 7
Pages 716-735
Date 07 2017
Journal Abbr Cancer Discov
Language eng
DOI 10.1158/2159-8290.CD-16-0441
ISSN 2159-8290
Library Catalog PubMed
Extra PMID: 28416471 PMCID: PMC5501738
Tags Animals, CD36 Antigens, Cell Line, Tumor, Cell Lineage, Cytarabine, Drug Resistance, Neoplasm, Humans, Leukemia, Myeloid, Acute, Mice, Neoplastic Stem Cells, original, Xenograft Model Antitumor Assays
Date Added 2024/12/03 - 09:12:56
Date Modified 2024/12/03 - 09:12:56
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés